OTLK Stock — Outlook Therapeutics Inc.: Cash, EV, Pipeline

Share price

$0.65

Market cap

$158.9M

Cash

$62.3M

Enterprise value

$96.6M

Balance sheet

Cash	$62.3M
Debt	$0.0M
Net cash	$62.3M
Enterprise value	$96.6M
Basic shares	187.1M shares
Fully diluted shares	290.0M shares
Fully diluted market cap	$188.5M
Cash per share	$0.33

Cash figures as of 2026-08-14. Database snapshot: 2026-09-21.

Price history

Loading OTLK daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	bevacizumab	Phase 3	Age-Related Macular Degeneration; Neovascular Age-related Macular Degeneration; Wet Macular Degeneration	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

LYTENAVA

Approved · Active Modality: biologic (monoclonal antibody)

Aliases ONS-5010, bevacizumab gamma, bevacizumab-vikg

Target VEGF

Indications

Wet age-related macular degeneration (wet AMD) (Approved)

Status note Ophthalmic formulation of bevacizumab for wet AMD; the Company's single product. FDA approved the BLA on July 24, 2026 (first and only FDA-approved ophthalmic formulation of bevacizumab in the U.S.; CRL received December 2025, Type A meeting March 2, 2026). European Commission granted Marketing Authorization in May 2024; commercial sales began in the UK, Germany, and Austria in June 2025. Company preparing for U.S. commercial launch.

Per-asset detail extracted from the 10-Q filed 2026-09-02. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	bevacizumab
Lead indication	Age-Related Macular Degeneration
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05112861	Phase 3	Active, not recruiting	Sponsor	OTLK	—	Age-Related Macular Degeneration; Neovascular Age-related Macular Degeneration; Wet Macular Degeneration	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Outlook Therapeutics, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

OTLK — Outlook Therapeutics Inc.